| Ms Kimberly Dawn Nolte, NP | |
|
150 S Ingleside St Ste 6, Fairhope, AL 36532-1804 | |
| (251) 990-1740 | |
| (251) 990-1831 |
| Full Name | Ms Kimberly Dawn Nolte |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 25 Years |
| Location | 150 S Ingleside St Ste 6, Fairhope, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184809691 | NPI | - | NPPES |
| 145466 | Medicaid | AL | |
| 51131838 | Other | AL | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 1-072405 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Hospital | Fairhope, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairhope Internal Medicine Pc | 6305884651 | 9 |
News Archive
Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.
Carrier screening for inherited genetic disorders is an important part of preconception and prenatal care for the nearly 4 million women who give birth in the US annually. Carrier screening is meant to identify couples at risk for passing on such genetic conditions to their children.
In an editorial published in CNS Spectrums, Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).
Some cellular proteins have multiple, and occasionally opposing, functions. Professor Adrian Krainer and colleagues at Cold Spring Harbor Laboratory demonstrate in a paper published online today in Molecular Cell that the oncogenic protein SRSF1 can also trigger a stop in cell growth and prevent cancerous proliferation by stabilizing p53, the powerful tumor-suppressor protein.
Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.
› Verified 9 days ago
| Entity Name | Fairhope Internal Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295760494 PECOS PAC ID: 6305884651 Enrollment ID: O20050419000175 |
News Archive
Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.
Carrier screening for inherited genetic disorders is an important part of preconception and prenatal care for the nearly 4 million women who give birth in the US annually. Carrier screening is meant to identify couples at risk for passing on such genetic conditions to their children.
In an editorial published in CNS Spectrums, Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).
Some cellular proteins have multiple, and occasionally opposing, functions. Professor Adrian Krainer and colleagues at Cold Spring Harbor Laboratory demonstrate in a paper published online today in Molecular Cell that the oncogenic protein SRSF1 can also trigger a stop in cell growth and prevent cancerous proliferation by stabilizing p53, the powerful tumor-suppressor protein.
Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kimberly Dawn Nolte, NP 188 Hospital Dr, Ste 402, Fairhope, AL 36532-2043 Ph: (251) 990-1740 | Ms Kimberly Dawn Nolte, NP 150 S Ingleside St Ste 6, Fairhope, AL 36532-1804 Ph: (251) 990-1740 |
News Archive
Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.
Carrier screening for inherited genetic disorders is an important part of preconception and prenatal care for the nearly 4 million women who give birth in the US annually. Carrier screening is meant to identify couples at risk for passing on such genetic conditions to their children.
In an editorial published in CNS Spectrums, Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).
Some cellular proteins have multiple, and occasionally opposing, functions. Professor Adrian Krainer and colleagues at Cold Spring Harbor Laboratory demonstrate in a paper published online today in Molecular Cell that the oncogenic protein SRSF1 can also trigger a stop in cell growth and prevent cancerous proliferation by stabilizing p53, the powerful tumor-suppressor protein.
Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.
› Verified 9 days ago
Janet Higgins, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 10657 County Road 1, Fairhope, AL 36532 Phone: 601-201-0004 | |
Anna Reid Tindle, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 188 Hospital Dr Ste 100, Fairhope, AL 36532 Phone: 251-607-9797 | |
Margaret Davis Kellar, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 374 Greeno Rd S, Fairhope, AL 36532 Phone: 251-450-2211 | |
Mrs. Sarah Mclaughlin Gonzalez, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3 Medical Park, Fairhope, AL 36532 Phone: 512-928-8804 | |
Frances T Fuller, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 770 Middle St, Fairhope, AL 36532 Phone: 251-928-1191 Fax: 251-928-4529 | |
Mrs. Debra Ann Langham, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 750 Morphy Avenue, Fairhope, AL 36533 Phone: 251-279-1605 Fax: 251-279-1606 |